Genmab A/S (NASDAQ:GMAB) Price Target Cut to $45.00 by Analysts at Truist Financial
Genmab A/S (NASDAQ:GMAB – Free Report) had its price target decreased by Truist Financial from $50.00 to $45.00 in a report published on Tuesday,Benzinga reports. Truist Financial currently has a buy rating on the stock. Other research analysts have also recently issued research reports about the company. Sanford C. Bernstein upgraded Genmab A/S from a […]
Genmab A/S (NASDAQ:GMAB – Free Report) had its price target decreased by Truist Financial from $50.00 to $45.00 in a report published on Tuesday,Benzinga reports. Truist Financial currently has a buy rating on the stock. Other research analysts have also recently issued research reports about the company. Sanford C. Bernstein upgraded Genmab A/S from a […]
